Abstract
Monocyte chemoattractant protein-1 (MCP-1), also known as CCL2, is a member of the CC family of chemokines. During inflammatory conditions, the production of MCP-1 is upregulated in both immune and non-immune cell types including macrophages, mast cells, fibroblasts, endothelial and epithelial cells, smooth muscle cells, and astrocytes. MCP-1 is a potent activator and chemoattractant of leukocytes such as monocytes, macrophages, activated T cells, dendritic cells, and natural killer (NK) cells [1]. The biological effects of MCP-1 are mediated by interaction with its primary receptor, CCR2. In addition to inducing chemotaxis, other cellular responses induced by MCP-1 include integrin activation, inflammatory cytokine production, and histamine release [2, 3].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Luster A (1998) Chemokines — chemotactic cytokines that mediate inflammation. New Eng J Med 338: 436–445
Biswas S, Sodhi A (2002) In vitro activation of murine peritoneal macrophages by MCP-1: Upregulation of CD11b, production of proinflammatory cytokines, and the signal transduction pathway. J Interferon Cytokine Res 22: 527–538
Bischoff S, Krieger M, Brunner T, Dahinden C (1992) MCP-1 is a potent activator of human basophils. J Exp Med 175: 1271–1275
Ogata H, Takeya M, Yoshimura T, Takagi K, Takahashi K (1997) The role of MCP-1 in the pathogenesis of collagen-induced arthritis in rats. J Pathol 182: 106–114
Kennedy K, Strieter R, Kunkel S, Lukacs N, Karpus W (1998) Acute and relapsing EAE are regulated by differential expression of the CC chemokines MIP-1α and MCP-1. J Neuroimmunol 92: 98–108
Inoue S, Egashira K, Ni W, Kitamoto S, Usui M, Otani K, Ishibashi M, Hiasa K, Nishida K, Takeshita A (2002) Anti-MCP-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E knockout mice. Circulation 106: 2700–2706
Gonzalo J, Lloyd C, Wen D, Albar J, Wells T, Proudfoot A, Martinez-A C, Dorf M, Bjerke T, Coyle A et al (1998) The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 188: 157–167
Wolf G, Jocks T, Zahner G, Panzer U, Stahl R (2002) Existence of a regulatory loop between MCP-1 and TGF-β in glomerular immune injury. Am J Physiol 283: F1075–F1084
Campbell E, Charo I, Kunkel S, Strieter R, Boring L, Gosling J, Lukacs N (1999) MCP-1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2-/- mice: The role of mast cells. J Immunol 163: 2160–2167
Dawson T, Kuziel W, Osahar T, Maeda N (1999) Absence of CCR2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 143: 205–211
Tesch G, Schwarting A, Kinoshita K, Lan H, Rollins B, Kelley V (1999) MCP-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J Clin Invest 103: 73–80
Alam R, York J, Boyars M, Stafford S, Grant J, Lee J, Forsythe P, Sim T, Ida N (1996) Increased MCP-1, RANTES, and MIP-1α in bronchoalveolar lavage fluid of allergic asthmatic patients. Am J Respir Crit Care Med 153: 1398–1404
Jahnz-Rozyk K, Kuna P, Pirozynska E (1997) MCP-1 in bronchoalveolar lavage fluid from patients with atopic asthma and chronic bronchitis. J Invest Allergol Clin Immunol 7: 254–259
Ellingsen T, Buus A, Stengaard-Pederson K (2001) Plasma MCP-1 is a marker for joint inflammation in rheumatoid arthritis. J Rheumatol 28: 41–46
Nelken N, Coughlin S, Gordon D, Wilcox J (1991) MCP-1 in human atheromatous plaques. J Clin Invest 88: 1121–1127
Simpson J, Newcombe J, Cuzner M, Woodroofe M (1998) Expression of MCP-1 and other β-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 84: 238–249
Szalai C, Kozma G, Nagy A, Bojszko A, Krikovszky D, Szabo T, Falus A (2001) Polymorphism in the gene regulatory region of MCP-1 is associated with asthma susceptibility and severity. J Allergy Clin Immunol 108: 375
Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, Mulkins M, Weatherhead G, Lapierre J, Dankwardt J et al (2000) Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists. J Biol Chem 275: 25562–25571
Witherington J, Bordas V, Cooper D, Forbes I, Gribble A, Ife R, Berkhout T, Gohil J, Groot P (2001) Conformationally restricted indolopiperidine derivatives as potent CCR2b receptor antagonists. Bioorg Med Chem Lett 11: 2177–2180
Kettle J, Faull A, Barker A, Davies D, Stone M (2004) N-Benzylindone-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor. Bioorg Med Chem Lett 14: 405–408
Rand M, Warren J, Mansour M, Newman W, Ringler D (1996) Inhibition of T cell recruitment and cutaneous delayed-type hypersensitivity-induced inflammation with antibodies to MCP-1. Am J Pathol 148: 855–864
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Birkhäuser Verlag Basel/Switzerland
About this chapter
Cite this chapter
Higgins, P.J., Schwartz, C.E., Nicolas, JM. (2007). Small molecule CCR2 antagonists. In: Neote, K., Letts, G.L., Moser, B. (eds) Chemokine Biology — Basic Research and Clinical Application. Progress in Inflammation Research. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-7437-2_9
Download citation
DOI: https://doi.org/10.1007/978-3-7643-7437-2_9
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-7195-1
Online ISBN: 978-3-7643-7437-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)